Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering... ORIGINAL ARTICLE Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014) Francesco Grossi, MD,* Riccardo Spizzo, MD, PhD,† Domenico Bordo, PhD,‡ Veronica Cacitti, MD,§ Francesca Valent, MD, Ciro Rossetto, MD,¶ Alessandro Follador, MD,¶ Silvia Di Terlizzi, MD,¶ Marianna Aita, MD,¶ Angelo Morelli, MD,# Gianpiero Fasola, MD,¶ Clara Consiglieri, PhD,‡ Tino Ceschia, MD,¶ Carlo A. Beltrami, MD,§ and Ornella Belvedere, MD¶** 0.042). In multivariate analysis, cyclin D1 was the only positive Introduction: Stage IIIA non-small cell lung cancer (NSCLC) with prognostic factor (p  0.0001). Unsupervised hierarchical clustering ipsilateral mediastinal lymph node metastases (N2) is a heteroge- analysis of TMA immunostaining data identified five distinct clusters. neous disease with differing prognoses. In this study, we retrospec- They formed two subsets of patients with better (clusters 1 and 2) and tively investigated the prognostic value of the expression of 10 worse (clusters 3, 4, and 5) prognoses, and median survival of 51 and molecular markers in 87 patients with stage IIIA pN2 NSCLC 10 months, respectively (p  0.0001). The better prognosis subset treated with radical surgery. mainly comprised patients with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)

Belvedere, Ornella
Journal of Thoracic Oncology , Volume 5 (9) – Sep 1, 2010
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/prognostic-stratification-of-stage-iiia-pn2-non-small-cell-lung-cancer-XAmT1tG0wh

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181e77a78
pmid
20631638
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014) Francesco Grossi, MD,* Riccardo Spizzo, MD, PhD,† Domenico Bordo, PhD,‡ Veronica Cacitti, MD,§ Francesca Valent, MD, Ciro Rossetto, MD,¶ Alessandro Follador, MD,¶ Silvia Di Terlizzi, MD,¶ Marianna Aita, MD,¶ Angelo Morelli, MD,# Gianpiero Fasola, MD,¶ Clara Consiglieri, PhD,‡ Tino Ceschia, MD,¶ Carlo A. Beltrami, MD,§ and Ornella Belvedere, MD¶** 0.042). In multivariate analysis, cyclin D1 was the only positive Introduction: Stage IIIA non-small cell lung cancer (NSCLC) with prognostic factor (p  0.0001). Unsupervised hierarchical clustering ipsilateral mediastinal lymph node metastases (N2) is a heteroge- analysis of TMA immunostaining data identified five distinct clusters. neous disease with differing prognoses. In this study, we retrospec- They formed two subsets of patients with better (clusters 1 and 2) and tively investigated the prognostic value of the expression of 10 worse (clusters 3, 4, and 5) prognoses, and median survival of 51 and molecular markers in 87 patients with stage IIIA pN2 NSCLC 10 months, respectively (p  0.0001). The better prognosis subset treated with radical surgery. mainly comprised patients with

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Sep 1, 2010

References

  • Treatment of non-small cell lung cancer—stage IIIA. ACCP Evidence-based clinical practice guidelines (2nd edition)
    Robinson
  • Current treatment paradigms for locally advanced non-small cell lung cancer
    Rigas
  • The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification of lung cancer
    Rusch
  • Validity of International Association for the Study of Lung Cancer Proposals for the revision of N descriptors in lung cancer
    Lee
  • Tissue microarrays for high-throughput molecular profiling of tumor specimens
    Kononen
  • A decade of tissue microarray progress in the discovery and validation of cancer biomarkers
    Camp
  • Potential role of multitargeted tyrosine kinase inhibitors in non-small-cell lung cancer
    Scagliotti
  • Ongoing and future trials of biologic therapies in lung cancer
    Bunn
  • Biology of interactions: anti-epidermal growth factor receptor agents
    Harari
  • Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments
    Steeghs
  • Development of matrix metalloproteinase inhibitors in cancer therapy
    Hidalgo
  • Drugging cell cycle kinases in cancer therapy
    Blagden
  • Lymph node mapping and curability at various levels of metastasis in resected lung cancer
    Naruke